| Local delivery and glioblastoma: why not combining sustained release and targeting? C Gazaille, M Sicot, P Saulnier, J Eyer, G Bastiat Frontiers in Medical Technology 3, 791596, 2021 | 18 | 2021 |
| Polymer-free hydrogel made of lipid nanocapsules, as a local drug delivery platform M Pitorre, C Gazaille, K Frankova, J Béjaud, N Lautram, J Riou, R Perrot, ... Materials Science and Engineering: C 126, 112188, 2021 | 13 | 2021 |
| Characterization of biological material adsorption to the surface of nanoparticles without a prior separation step: a case study of glioblastoma-targeting peptide and lipid … C Gazaille, M Sicot, M Akiki, N Lautram, A Dupont, P Saulnier, J Eyer, ... Pharmaceutical Research 38, 681-691, 2021 | 13 | 2021 |
| TRPC3, but not TRPC1, as a good therapeutic target for standalone or complementary treatment of DMD A Creisméas, C Gazaille, A Bourdon, MA Lallemand, V François, M Allais, ... Journal of translational medicine 19, 1-17, 2021 | 11 | 2021 |
| GC01, a first-in-class antimitotic peptide for the treatment of glioblastoma and other aggressive cancers of the nervous system C Gazaille, C Lépinoux-Chambaud Innovations & Thérapeutiques en Oncologie 8 (1), 59-63, 2022 | | 2022 |
| GC01, un peptide antimitotique « first-in-class » pour le traitement du glioblastome et d’autres cancers agressifs du système nerveux C Gazaille, C Lépinoux-Chambaud Innovations & Thérapeutiques en Oncologie 8 (1), 59-63, 2022 | | 2022 |
